BOSTON, Dec. 11 /PRNewswire/ -- Surface Logix Inc. announced that Jim
Mahoney, President and Chief Executive Officer, will participate on two
panel discussions at the RBC Capital Markets Healthcare Conference this
week at the Westin Times Square Hotel in New York.
During the "New Targets for Lipid Control" panel on Wednesday, December
13, 2006, from 9:00 to 9:55 AM, Mr. Mahoney will provide insight into the
clinical development of SLx-4090, a first-in-class enterocyte-specific MTP
inhibitor that acts selectively in the gastrointestinal tract to target
unmet needs in dyslipidemia, metabolic disorders and obesity, and is
entering a Phase 2a trial.
On Thursday, December 14, from 9:00 to 9:55 AM, Mr. Mahoney will
participate on the "Better Chemistry = Better Drugs" panel, with details
how the Surface Logix Pharmacomer Technology Platform has driven the
directed design and successful introduction of two new drugs into clinical
trials in less than 3 years.
Surface Logix Inc. currently has two programs in human clinical trials
with a third program approaching its initial regulatory submission.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to
create new small molecule drugs that are optimized to meet the challenges
of human physiology. The company is advancing multiple internal programs
focused primarily on cardiovascular, metabolic, inflammatory and fibrotic
diseases. For more information, please visit http://www.surfacelogix.com.
Contact:
Warwick Tong MB ChB
Surface Logix Inc.
Senior Vice President, Commercial Development
617.746.8505
Media:
Kari Watson
MacDougall Biomedical Communications Inc.
kwatson@macbiocom.com
508.647.0209
SOURCE Surface Logix Inc.
 back to top
Related links:
http://www.macbiocom.com
http://www.surfacelogix.com
CONTACT:
Warwick Tong MB ChB, of Surface Logix Inc.,
Senior Vice President, Commercial Development, +1-617-746-8505;
or Media, Kari Watson, of MacDougall Biomedical Communications
Inc., +1-508-647-0209, or e-mail kwatson@macbiocom.com
|
